替格瑞洛在急性冠脉综合征患者介入治疗中的应用效果

摘要

目的：探究替格瑞洛在急性冠脉综合征患者介入治疗中的临床应用效果。方法选取2014年2月~2016年5月于广东省高州市人民医院收治的急性冠脉综合征患者112例，随机分为观察组与对照组，每组56例。两组患者均给予经皮冠状动脉内支架植入（PCI）治疗，在此基础上，观察组术后服用替格瑞洛，对照组服用氯吡格雷。观察两组患者治疗前后TIMI血流变化和血小板计数及血小板聚集率，比较两组不良反应差异和两组出血情况。结果治疗前两组患者的TIMI血流变化无显著差异（P＞0.05），治疗后两组患者TIMI血流变化较治疗前均明显改善（P＜0.05），且与对照组相比，观察组改善更加明显（P＜0.05）。治疗前两组患者血小板计数无显著差异（P＞0.05），治疗后两组血小板聚集率均较治疗前有所下降（P＜0.05），且与对照组相比，观察组下降更加明显（P＜0.05）。治疗后观察组不良反应发生率为5.36%，对照组为17.86%，观察组不良反应发生率明显低于对照组（P＜0.05）。治疗后观察组出血发生率为5.36%，对照组为7.14%，两组出血发生率无显著差异（P＞0.05）。结论替格瑞洛在急性冠脉综合征患者介入治疗中的临床效果显著，不良反应较少，有临床应用价值。%Objective To explore the clinical effect of ticagrelor in patients with acute coronary syndromes undergoing interventional therapy.Methods 112 patients with acute coronary syndrome admitted in Gaozhou People's Hospital from February 2014 to May 2016 were randomly divided into the observation group and the control group, with 56 patients in each group. Patients in both groups were treated with percutaneous coronary stenting (PCI). On the basis of this, the patients in the observation group were treated with ticagrelor and the control group received clopidogrel. The changes of TIMI blood flow, platelet count and platelet aggregation rate were observed before and after treatment. The difference of adverse reactions between the two groups and the hemorrhage of the two groups were observed.Results There was no significant difference in TIMI blood flow between the two groups before treatment (P>0.05). The changes of TIMI blood flow in the two groups after treatment were significantly improved (P<0.05). Compared with the control group, the improvement was more obvious (P<0.05). There was no significant difference in platelet count between the two groups before treatment (P>0.05). After treatment, the platelet aggregation rate in the two groups decreased compared with that before treatment (P<0.05), and the decrease was more obvious in the observation group than that in the control group (P<0.05). The adverse reaction rate was 5.36%in the observation group and 17.86% in the control group. The adverse reaction rate in the observation group was significantly lower than that in the control group (P<0.05). The bleeding rate was 5.36% in the observation group and 7.14% in the control group. There was no significant difference in bleeding rate between the two groups (P>0.05). Conclusion Ticagrelor is clinically effective with fewer adverse reactions in interventional treatment of patients with acute coronary syndrome significant, which should be promoted.